ERRATUM

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Philippe Moreau¹ · Niels W. C. J. van de Donk² · Jesus San Miguel³ · Henk Lokhorst² · Hareth Nahi⁴ · Dina Ben-Yehuda⁵ · Michele Cavo⁶ · Gordon Cook⁷ · Michel Delforge⁸ · Hermann Einsele⁹ · Sonja Zweegman² · Heinz Ludwig¹⁰ · Christoph Driessen¹¹ · Antonio Palumbo¹² · Thierry Facon¹³ · Torben Plesner¹⁴ · Meletios Dimopoulos¹⁵ · Pia Sondergeld¹⁶ · Pieter Sonneveld¹⁷ · María-Victoria Mateos¹⁸

Published online: 20 May 2016
© Springer International Publishing Switzerland 2016

Erratum to: Drugs DOI 10.1007/s40265-016-0573-4

Table 4, which previously appeared as

Table 4 Management considerations concerning monoclonal antibody use in hematology in general, and myeloma in particular

	CD38 monoclonal antibodies				
	Rituximab	Elotuzumab	Daratumumab	Isatuximab	MOR202
Infusion-related reactions	×	×	×	×	×
Interference with response assessment	×	×	×	×	×
Interference with blood typing			×	×	×

The online version of the original article can be found under doi:[10.1007/s40265-016-0573-4](https://doi.org/10.1007/s40265-016-0573-4).

✉ Philippe Moreau
philippe.moreau@chu-nantes.fr

- ¹ Hematology Department, University Hospital Hôtel-Dieu, Place Ricordeau, 44093 Nantes, France
- ² VU University Medical Center, Amsterdam, The Netherlands
- ³ University Hospital Navarra, Pamplona, Spain
- ⁴ Karolinska University Hospital Huddinge, Stockholm, Sweden
- ⁵ Hadassah Medical Center, Jerusalem, Israel
- ⁶ University School of Medicine, Bologna, Italy
- ⁷ St James's University Hospital, Leeds, UK
- ⁸ Catholic University of Leuven, Leuven, Belgium

- ⁹ Julius Maximilian University, Würzburg, Germany
- ¹⁰ Wilhelminen hospital, Vienna, Austria
- ¹¹ Kantonsspital St. Gallen, St. Gallen, Switzerland
- ¹² University of Torino, Torino, Italy
- ¹³ University Hospital Lille, Lille, France
- ¹⁴ Vejle Hospital and University of Southern Denmark, Vejle, Denmark
- ¹⁵ University Athens School of Medicine, Athens, Greece
- ¹⁶ University of Giessen, Giessen, Germany
- ¹⁷ Erasmus MC Cancer Institute, Rotterdam, The Netherlands
- ¹⁸ University Hospital of Salamanca, Salamanca, Spain

Should appear as

Table 4 Management considerations concerning monoclonal antibody use in hematology in general, and myeloma in particular

	Rituximab	Elotuzumab	CD38 monoclonal antibodies		
			Daratumumab	Isatuximab	MOR202
Infusion-related reactions	×	×	×	×	×
Interference with response assessment	×	×	×	×	×
Interference with blood typing			×	×	×